Genmab AS - Company Profile

Powered by

All the data and insights you need on Genmab AS in one report.

$395 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Genmab AS Strategy Report

  • Understand Genmab AS position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Genmab AS: Overview

Select Item

Related keylists

Genmab AS (Genmab) is a biotechnology company that develops differentiated human antibody therapies for the treatment of cancer and other diseases. The company's marketed antibodies include ofatumumab (Kesimpta) for the treatment of relapsing multiple sclerosis, daratumumab (Darzalex) for the treatment of AL amyloidosis and multiple myeloma, and teprotumumab (Tepezza) for thyroid eye disease. Its products are based on proprietary antibody technologies, namely, HexaBody, DuoBody, DuoHexaBody, and HexElect technologies. The company works in partnership with various pharmaceutical and biotechnology companies for the co-development and commercialization of antibody-based products. It operates in Denmark, the Netherlands, Japan and the US. Genmab is headquartered in Copenhagen, Denmark.

 Gain a 360-degree view of Genmab AS and make more informed decisions for your business Gain a 360-degree view of Genmab AS and make more informed decisions for your business Find out more
Headquarters Denmark
Address Kalvebod Brygge 43, Koebenhavn V, 1560
Website www.genmab.com
Telephone 45 70202728
No of Employees 2,132
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange GMAB (CPH)
Revenue (2022) $2.1B 72.1% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 83.6% (2022 vs 2021)
Market Cap* $21.0B
Net Profit Margin (2022) XYZ 6.7% (2022 vs 2021)
* As of and is in US$
View Genmab AS financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Genmab AS premium industry data and analytics

130+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Genmab AS’s relevant decision makers and contact details.

90+

Catalyst Calendar

Proactively evaluate Genmab AS’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

90+

Clinical Trials

Determine Genmab AS go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

70+

Pipeline Drugs

Identify which of Genmab AS’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

50+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

9

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

2

Marketed Drugs

Understand Genmab AS’s commercialized product portfolio to stay one step ahead of the market.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Genmab AS’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Kesimpta (Ofatumumab) – Relapsing Multiple Sclerosis Darzalex
Darzalex (Daratumumab) – Multiple Myeloma Tepezza
Tepezza (Teprotumumab) – Thyroid Eye Disease Kesimpta
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Genmab AS portfolio and identify potential areas for collaboration Understand Genmab AS portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Regulatory Approval In September, the company secured conditional marketing authorization from the European Commission for TEPKINLY as a monotherapy to treat adults with relapsed or refractory diffuse large B-cell lymphoma.
2023 Regulatory Approval In May, the company announced that the U.S. Food and Drug Administration (FDA) approved EPKINLY (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
2023 Contracts/Agreements In April, the company and argenx entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology and oncology therapeutic areas.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Genmab AS Bayer AG Sanofi Takeda Pharmaceutical Co Ltd Amgen Inc
Headquarters Denmark Germany France Japan United States of America
City Koebenhavn V Leverkusen Paris Chuo-Ku Thousand Oaks
State/Province - Nordrhein-Westfalen Ile-de-France Tokyo California
No. of Employees 2,132 100,873 91,573 49,095 25,200
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Deirdre P. Connelly Chairman Executive Board 2017 62
Jan G. J. Van de Winkel, Ph.D. Chief Executive Officer; President Senior Management 2010 61
Anthony Pagano Executive Vice President; Chief Financial Officer Senior Management 2020 45
Anthony Mancini Executive Vice President; Chief Operating Officer Senior Management 2020 52
Martine van Vugt Executive Vice President; Chief Strategy Officer Senior Management 2023 -
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Gain insight into Genmab AS key executives to enhance your sales strategy Gain insight into Genmab AS key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward